Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Degeneracy, as opposed to specificity, in immunotherapy.

Literature DB >> 11877465

Degeneracy, as opposed to specificity, in immunotherapy.

David A Hafler¹.

Abstract

Mesh：

Substances：

Year: 2002 PMID： 11877465 PMCID： PMC150898 DOI： 10.1172/JCI15198

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

× No keyword cloud information.

27 in total

1. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Authors: B Bielekova; B Goodwin; N Richert; I Cortese; T Kondo; G Afshar; B Gran; J Eaton; J Antel; J A Frank; H F McFarland; R Martin
Journal: Nat Med Date: 2000-10 Impact factor: 53.440

2. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99.

Authors: L J Ausubel; J I Krieger; D A Hafler
Journal: J Immunol Date: 1997-09-01 Impact factor: 5.422

3. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.

Authors: L B Nicholson; A Murtaza; B P Hafler; A Sette; V K Kuchroo
Journal: Proc Natl Acad Sci U S A Date: 1997-08-19 Impact factor: 11.205

4. Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones.

Authors: D E Anderson; L J Ausubel; J Krieger; P Höllsberg; G J Freeman; D A Hafler
Journal: J Immunol Date: 1997-08-15 Impact factor: 5.422

5. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

Authors: P W Duda; M C Schmied; S L Cook; J I Krieger; D A Hafler
Journal: J Clin Invest Date: 2000-04 Impact factor: 14.808

6. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules.

Authors: M Fridkis-Hareli; J L Strominger
Journal: J Immunol Date: 1998-05-01 Impact factor: 5.422

7. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

Authors: L Kappos; G Comi; H Panitch; J Oger; J Antel; P Conlon; L Steinman
Journal: Nat Med Date: 2000-10 Impact factor: 53.440

8. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

Authors: O Neuhaus; C Farina; A Yassouridis; H Wiendl; F Then Bergh; T Dose; H Wekerle; R Hohlfeld
Journal: Proc Natl Acad Sci U S A Date: 2000-06-20 Impact factor: 11.205

9. Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein.

Authors: L J Ausubel; K D Bieganowska; D A Hafler
Journal: Cell Immunol Date: 1999-04-10 Impact factor: 4.868

10. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone.

Authors: B Hemmer; B T Fleckenstein; M Vergelli; G Jung; H McFarland; R Martin; K H Wiesmüller
Journal: J Exp Med Date: 1997-05-05 Impact factor: 14.307

8 in total

1. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure.

Authors: Sharon Bakalash; Gil Ben-Shlomo; Gil Ben Shlomo; Eyal Aloni; Iftach Shaked; Larry Wheeler; Ron Ofri; Michal Schwartz
Journal: J Mol Med (Berl) Date: 2005-08-12 Impact factor: 4.599

Degeneracy, as opposed to specificity, in immunotherapy.

1. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

2. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99.

3. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.

4. Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones.

5. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

6. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules.

7. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

8. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

9. Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein.

10. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone.

1. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure.

2. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.

3. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.

4. Degeneracy allows for both apparent homogeneity and diversification in populations.

5. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes.

Review 6. Hit-Hit and hit-Run: viruses in the playing field of multiple sclerosis.

7. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas.

8. Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.